末梢動脈疾患(PAD)の疫学的予測(~2024)

◆英語タイトル:EpiCast Report: Peripheral Arterial Disease - Epidemiology Forecast to 2024
◆商品コード:GDHCER090-15
◆発行会社(調査会社):GlobalData
◆発行日:2015年10月6日
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥455,430見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥910,860見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,366,290見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、末梢動脈疾患(PAD)の疫学的市場予測について調査・分析し、以下の構成でお届けいたします。

・イントロダクション
・末梢動脈疾患(PAD)の概要
・リスク要因及び併存症
・主要地域の動向
・疫学的予測方法
・末梢動脈疾患(PAD)の疫学的予測結果(有病率など)
・考察(結論、分析の限界・強み)
【レポートの概要】

EpiCast Report: Peripheral Arterial Disease – Epidemiology Forecast to 2024

Summary

Peripheral artery disease (PAD) refers to conditions that result in the obstruction of blood flow in the arteries, predominantly in the coronary and intercranial vessels, and may also refer to complications with the extracranial carotid circulation and the upper extremity arteries. However, the general focus of PAD research is on chronic arterial occlusive disease of the arteries in the legs, primarily caused by atherosclerosis. PAD is typically divided into four clinical stages with increasing degrees of severity: Stage I, Stage II, Stage III, and Stage IV based on the Fontaine classification.

GlobalData epidemiologists forecast an increase in the total prevalent cases of PAD in the 8MM, from 66,433,407 in 2014 to 94,490,894 cases in 2024 with an annual growth rate (AGR) of 4.22%. Additionally the number of diagnosed incident cases of PAD is expected to grow from 7,900,097 cases in 2014 to 10,797,781 cases in 2024 at an AGR of 3.67%.

GlobalData epidemiologists used comprehensive country-specific data from population-based studies, which were published in peer-reviewed journal articles, to arrive at a meaningful, in-depth analysis and forecast for the total and diagnosed prevalent cases of PAD, asymptomatic and symptomatic cases of PAD, PAD cases with IC, cases of PAD with CLI, cases of PAD with comorbid hypertension, and cases of PAD with comorbid diabetes. Additionally, sex- and age-specific segmentation for the total prevalent cases and the diagnosed prevalent cases of PAD was obtained. Furthermore, GlobalData epidemiologists ensured that all the studies used to obtain the data regarding the total prevalence of PAD across the 8MM used the gold standard diagnosis definition, where patients are only considered to have PAD if they have an ABPI less than or equal to 0.9, thereby allowing for meaningful comparisons of the segmentation populations across the 8MM.

Scope

- The Peripheral Arterial Disease (PAD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for PAD in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Urban China). It includes a 10-year epidemiological forecast of the total and diagnosed prevalent cases of PAD segmented by sex and age (beginning at 35 years and ending at =85 years) in these markets. Additionally, both the total and diagnosed prevalent cases of PAD are further segmented in symptomatic PAD, asymptomatic PAD, PAD with intermittent claudication (IC), PAD with critical limb ischemia (CLI), PAD with hypertension, and PAD with diabetes.
- The PAD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The PAD EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global PAD market.
- Quantify patient populations in the global PAD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for PAD therapeutics in each of the markets covered.

【レポートの目次】

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 10
3 Disease Background 11
3.1 Risk Factors and Comorbidities 12
3.2 Global Trends 14
3.3 Forecast Methodology 15
3.3.1 Sources Used 16
3.3.2 Sources Not Used 29
3.3.3 Forecast Assumptions and Methods 30
3.4 Epidemiological Forecast of Total Prevalent Cases of PAD (2014-2024) 35
3.4.1 Total Prevalent Cases of PAD 35
3.4.2 Age-Specific Total Prevalent Cases of PAD 37
3.4.3 Sex-Specific Total Prevalent Cases of PAD 38
3.4.4 Age-Adjusted Total Prevalence of PAD 40
3.4.5 Total Prevalent Asymptomatic and Symptomatic Cases of PAD 41
3.4.6 Total Prevalent Cases of PAD with Intermittent Claudication and PAD with Critical Limb Ischemia 43
3.4.7 Proportion of Total PAD Cases that Present as Asymptomatic, PAD with Intermittent Claudication, and PAD with Critical Limb Ischemia 45
3.4.8 Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes 46
3.5 Epidemiological Forecast of Diagnosed Prevalent Cases of PAD (2014-2024) 48
3.5.1 Diagnosed Prevalent Cases of PAD 48
3.5.2 Age-Specific Diagnosed Prevalent Cases of PAD 50
3.5.3 Sex-Specific Diagnosed Prevalent Cases of PAD 52
3.5.4 Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD 54
3.5.5 Diagnosed Prevalent Cases of PAD with Intermittent Claudication and PAD with Critical Limb Ischemia 56
3.5.6 Proportion of Diagnosed PAD Cases that Present as Symptomatic, PAD with Intermittent Claudication, and PAD with Critical Limb Ischemia 58
3.5.7 Diagnosed Prevalent Cases of PAD with Hypertension and PAD Cases with Diabetes 59
3.6 Discussion 61
3.6.1 Epidemiological Forecast Insight 61
3.6.2 Limitations of the Analysis 62
3.6.3 Strengths of the Analysis 63
4 Appendix 64
4.1 Bibliography 64
4.2 Primary Research – Prescriber Survey 67
4.3 About the Authors 68
4.3.1 Epidemiologists 68
4.3.2 Reviewers 68
4.3.3 Global Director of Therapy Analysis and Epidemiology 69
4.3.4 Global Head of Healthcare 69
4.4 About GlobalData 70
4.5 About EpiCast 70
4.6 Disclaimer 71

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for PAD 13
Table 2: 8MM, Sources of Epidemiological Data Used to Forecast the Total Prevalent Cases of PAD 16
Table 3: 8MM, Sources of Epidemiological Data Used to Forecast Symptomatic and Asymptomatic Total Prevalent Cases of PAD 17
Table 4: 8MM, Sources of Epidemiological Data Used to Forecast the IC and CLI Total Prevalent Cases of PAD 18
Table 5: 8MM, Sources of Epidemiological Data Used to Forecast Total Prevalent Cases of PAD with Hypertension or Diabetes 19
Table 6: 8MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of PAD 20
Table 7: 8MM, Sources of Epidemiological Data Used to Forecast Asymptomatic and Symptomatic Diagnosed Prevalent Cases of PAD 21
Table 8: 8MM, Sources of Epidemiological Data Used for the Forecast of the Proportion of the Diagnosed PAD Population that Presents with IC 22
Table 9: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of PAD with Hypertension or Diabetes 23
Table 10: 8MM, Total Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024 36
Table 11: 8MM, Age-Specific Total Prevalent Cases of PAD, Both Sexes, N (Row %), 2014 37
Table 12: 8MM, Sex-Specific Total Prevalent Cases of PAD, Ages ≥35 Years, N (Row %), 2014 39
Table 13: 8MM, Total Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N (Row %), 2014 42
Table 14: 8MM, Total Prevalent Cases of PAD with IC and PAD with CLI, Both Sexes, Ages ≥35 Years, N , 2014 44
Table 15: 8MM, Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N (Row %), 2014 47
Table 16: 8MM, Diagnosed Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024 49
Table 17: 8MM, Age-Specific Diagnosed Prevalent Cases of PAD, Both Sexes, N, 2014 51
Table 18: 8MM, Sex-Specific Diagnosed Prevalent Cases of PAD, Ages ≥35 Years, N (Row %), 2014 53
Table 19: 8MM, Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N (Row %), 2014 55
Table 20: 8MM, Diagnosed Prevalent Cases of PAD with IC or CLI, Both Sexes, Ages ≥35 Years, N, 2014 57
Table 21: 8MM, Diagnosed Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N (Row %), 2014 60
Table 22: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 67

1.2 List of Figures
Figure 1: 8MM, Patient Flow for the Epidemiological Forecast of PAD 16
Figure 2: 8MM, Total Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024 36
Figure 3: 8MM, Age-Specific Total Prevalent Cases of PAD, Both Sexes, N, 2014 38
Figure 4: 8MM, Sex-Specific Total Prevalent Cases of PAD, Ages ≥35 Years, N, 2014 40
Figure 5: 8MM, Age-Standardized Total Prevalence of PAD, 2014 41
Figure 6: 8MM, Total Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N, 2014 43
Figure 7: 8MM, Total Prevalent Cases of PAD with IC and PAD with CLI, Both Sexes, Ages ≥35 Years, N, 2014 45
Figure 8: 8MM, Proportion of Total PAD Cases that Present as Asymptomatic, PAD with IC, and PAD with CLI, Both Sexes, Ages ≥35 Years, % 46
Figure 9: 8MM, Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N, 2014 48
Figure 10: 8MM, Diagnosed Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024 50
Figure 11: 8MM, Age-Specific Diagnosed Prevalent Cases of PAD, Both Sexes, N, 2014 52
Figure 12: 8MM, Sex-Specific Diagnosed Prevalent Cases of PAD, Ages ≥35 Years, N, 2014 54
Figure 13: 8MM, Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N, 2014 56
Figure 14: 8MM, Diagnosed Prevalent Cases of PAD with IC or CLI, Both Sexes, Ages ≥35 Years, N, 2014 58
Figure 15: 8MM, Proportion of Diagnosed PAD Cases that Present as Asymptomatic, PAD with IC, and PAD with CLI, Both Sexes, Ages ≥35 Years, %, 2014 59
Figure 16: 8MM, Diagnosed Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N, 2014 61

★調査レポート[末梢動脈疾患(PAD)の疫学的予測(~2024)]販売に関する免責事項
★調査レポート[末梢動脈疾患(PAD)の疫学的予測(~2024)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆